GM-CSF is known to prime leukocytes for inflammatory stimuli in vitro. The objective of this study was to investigate the role of GM-CSF in vivo in a systemic inflammatory reaction syndrome. The results demonstrate a potentiation ofLPS toxicity by GM-CSF in a mortality model as well as in a septic liver failure model in mice.
Introduction
Granulocyte macrophage colony-stimulating factor (GM-CSF) is a 23-kD glycoprotein which stimulates the proliferation and differentiation ofgranulocytic and monocytic progenitor cells. Known cellular sources of this hemopoietic growth factor are macrophages, endothelial cells, fibroblasts, and Tlymphocytes ( 1). In addition to the effects on hemopoietic stem cells, GM-CSF exhibits proinflammatory properties on mature neutrophils, eosinophils, and macrophages, such as the priming effect on neutrophils for activation with a second stimulus (2) (3) (4) , regulation ofleukocyte adhesion (5-7), augmentation of antigen presentation (8) , and enhancement or induction of cytokine production by neutrophils or macrophages (9) (10) (11) (12) . The hemopoietic properties ofGM-CSF prompted the treatment of cancer patients with this cytokine: GM-CSF was shown to accelerate granulocyte/monocyte recovery after chemotherapy or bone marrow transplantation (13) (14) (15) .
Endotoxins (lipopolysaccharides, LPSs) are potent inducers of CSF production in vivo. The injection of LPS increases serum CSF levels in mice in the 2-9 h after administration ( 16) . The LPS-inducible cytokines, TNFa or IL-1 stimulate GM-CSF production in macrophages, endothelial cells, and fibroblasts in vitro ( 15, 17, 18) . On the other hand, LPSinduced TNF and IL-1 production of monocytic cells was shown to be potentiated or induced by GM-CSF ( 19, 20) .
We recently have demonstrated that granulocyte CSF (G-CSF) reduced LPS-induced TNF release in vivo and ex vivo and thereby protected rodents against LPS shock and LPS hepatotoxicity (21 ) . In that study, we also noticed that GM-CSF pretreatment significantly enhanced LPS-induced TNF release in vivo and increased mortality in galactosamine (GalN)-sensitized mice. We now report that GM-CSF potentiates LPS toxicity by stimulating the production ofproinflammatory mediators such as TNF and IL-1. For these studies, we chose two different in vivo models of LPS-induced toxicity: In the first, a high dose of purified LPS was administered to induce septic shock with mortality as an endpoint. In the alternative model, i.e., endotoxin-induced liver injury in GalN-sensitized mice, serum transaminase release 8 h after challenge allowed the quantification of septic organ failure (22) . As in the case of LPS-induced mortality (23) , anti-mouse TNF antiserum also protected against LPS-induced hepatic failure in GalN-sensitized mice, emphasizing the common final pathway in either model (24) . The biochemical basis of the GalN model is the fact that this aminosugar depletes intracellular uridine nucleotides selectively within the liver, leading to an inhibition of hepatic transcription (25) , and thereby sensitizes mice towards LPS toxicity several thousand-fold (26). The organotropic toxicity of LPS mainly on the liver can be conveniently measured by determination of liver specific enzymes within the sera of the animals (22) . There is ample evidence in the literature that the GalN model may resemble some important aspects ofclinical reality: hepatic dysfunction develops frequently and early in sepsis (27) and continuously aggravates a vicious circle in the late phase ofmultiorgan failure, that consists ofenhanced bacterial translocation due to loss of intestinal barrier function. This is potentiated by allowing gut-derived bacterial products to circulate because of impaired hepatic reticuloendothelial clearance (28) .
The aim ofthis study was to investigate the role ofGM-CSF was withdrawn by heart puncture after cervical dislocation. Endotoxin shock experiments were performed by injecting 3-5 mg/kg LPS i.p. in BALB/c mice; survival was monitored until 72 h after challenge. In these experiments, blood samples for assessment of cytokines were obtained from the tail vein.
In vitro TNF and IL-] determination in bone marrow cell cultures. Bone marrow cells of NMRI mice were isolated according to Metcalf (see reference 31). 5 X i0' cells per 0.5 ml RPMI 1640, 100 U/ml penicillin, 100 U/ml streptomycin, 2 mM L-glutamine, 10% heat-inactivated fetal calf serum (Biochrom) were incubated for the indicated time intervals at 37°C, 5% CO2. Supernatants were stored at -700C.
Ex vivo IL-I determination in spleen cell supernatants. After incubation for 4 h at 37°C, 5% C02, cells were lysed by addition of 50 ,u of20% SDS wt/vol in 0.02 N HCI. Plates were read 18 h later on a SLT EAR 400 microplate reader, with a test wavelength of 560 nm and a reference wavelength of 690 nm. The titer of IL-1 was calculated in units per ml; one unit is defined as the reciprocal ofthe dilution providing 50% ofmaximal proliferation. IL-l is expressed in picograms (pg) per ml, using an internal recombinant murine IL-13 standard. The specificity of the proliferation for IL-I was checked with a monoclonal goat anti-mouse IL-13 antibody (IgG; Hermann Biermann GmbH, Bad Nauheim, Germany) and a polyclonal goat anti-mouse IL-1a specific antiserum (provided by Dr. H.-U. Beuscher, University of Erlangen, Germany).
TNF assay. TNF in serum of mice was determined essentially as described by Espevik and Nissen-Meyer (30) . In brief, Fibrosarcoma cells (WEHI 164 clone 13, provided by Dr. T. Espevik, University of Trondheim, Norway) at a concentration of 2 X 104 cells per 200 Ai were incubated with serially diluted test samples in 96-well flat-bottom microtiter plates and incubated for 18 h at 37°C and 5% CO2. Then, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (5 mg/ml; 1/10 [vol/vol]) was added for determination of cytotoxicity. After incubation for 4 h at 37°C in the presence of 5% CO2, the dye was removed and cells were lysed by the addition of 100 ,ul of isopropanol/5% formic acid. Plates were read as described in the IL-I assay. TNF is expressed in pg/ml, calculated with the use of a recombinant murine TNFa standard.
GM-CSF ELISA. GM-CSF ELISA kits were purchased from Endogen Inc. Control mouse serum (30% in supplied standard diluent) was used as blocking buffer and for preparation of standard curves. The assay did not cross-react with murine TNF according to the manufacturer's informations. In our hands, there was also no cross-reactivity with murine IL-I a or IL-IB.
IL-6 ELISA. IL-6 ELISA was performed using Pharmingen antibodies according to the manufacturer's instructions.
Soft-agar assayfor CSFs. Murine bone marrow cells were isolated as described elsewhere ( 31 ) . Bacto-agar was dissolved in H20 at 95°C in a concentration of 3% (w/vol). The agar solution was diluted with IMDM medium at 37°C to a final concentration of 0.3%. 2 X I05 bone marrow cells per ml agar were added to 200 ,ul test sample in a six-well cell culture plate.
The final serum concentration in the assay was 1%. After congealing at room temperature, the plates were incubated at 37°C, 5% CO2 for phological shape and by the lack of growth in presence of an anti-mouse GM-CSF antibody. TNF, IL-1, or LPS did not interfere with this test.
Enzyme assay procedure. ALT activities in plasma were determined in an automated enzyme activity assay based on that described previously (22) .
Statistics. 
Results
Priming by GM-CSF In vitro studies. GM-CSF was shown to prime monocytes in vitro for endotoxin-induced TNF-dependent cytotoxicity ( 19) and for enhanced IL-1 release upon LPS stimulation (20) . To study this priming effect of GM-CSF towards LPS in vivo in mice, we first evaluated GM-CSF priming towards cytokine producing murine cells in vitro. Preincubation with GM-CSF of freshly prepared bone marrow cells enhanced LPS-induced TNF release by a factor of 14 ( Fig. 1 a) . In the same cell culture supernatants we also found increased levels of IL-1 (Fig. 1 b) . Using specific neutralizing antibodies, 60% of the LPS-induc- In vivo studies. Next we examined whether priming for enhanced cytokine release takes place in vivo and which consequences arise from this phenomenon in endotoxic shock models in animals. In a lethality model ofLPS toxicity, all BALB/c mice pretreated with 50 ,g/kg GM-CSF before subtoxic LPS challenge (3 mg/kg) died within 24 h, whereas all animals which had received LPS alone, survived > 72 h (n = 6). Serum TNF levels 1.5 h after challenge were significantly enhanced by GM-CSF pretreatment compared to LPS challenge alone (17.6±3.3 ng/ml vs. 0.8±0.1 ng/ml; P < 0.05). In a parallel experiment, IL-6 concentrations were also significantly enhanced at the same time point from 31.9±1.4 ng/ml in the control group to 105.1±3.7 ng/ml in the pretreated group (P < 0.05; n = 3). GM-CSF treatment alone did not induce detectable amounts of TNF or To further investigate the role of GM-CSF in modulating LPS toxicity, we used an alternative in vivo model of septic shock, i.e., LPS-induced liver failure in GalN-sensitized mice. NMRI mice treated simultaneously with 700 mg/kg GalN and 5 ,ug/kg LPS i.p. developed severe liver injury within 8 h as shown by increased activities of the liver specific enzyme alanine aminotransferase (ALT) in the sera of the animals. Liver injury was preceded by the release of TNF into the circulation with maximal serum TNF concentrations 90 min after challenge (first group in Table I (Fig. 2) . All the LPS-inducible spleen cell derived IL-1 turned out to be IL-1 a, since it was blocked by a polyclonal anti-mouse IL-1 a specific antiserum. Circulating GM-CSF in LPS treated mice The observation that GM-CSF not only potentiated LPS-induced TNF production when given before LPS, but also when given 30 min after LPS, prompted us to investigate the role of endogenously produced GM-CSF following LPS administration. Fig. 3 shows the time course ofGM-CSF and TNF induced by 3 mg/kg LPS. 1 h after LPS administration, considerable amounts of GM-CSF were found in the sera of the animals. Maximal GM-CSF concentrations were reached 2 h after injection ofLPS. The experiment in Fig. 3 demonstrates further that the initial time courses of GM-CSF and TNF release are very similar. However, while TNF disappears very rapidly from the circulation, GM-CSF concentrations decline more slowly. In the other model used, i.e., GalN/LPS-induced liver damage, no GM-CSF was detectable in sera ofthese animals by ELISA. Because only small amounts of LPS are required in the GalN/ Mean values ±SEM; n = 6. *P < 0.05 vs. GalN/LPS alone. LPS model compared to LPS induced shock, serum GM-CSF levels might have been below the detection limit of the assay. An alternative method of determining colony stimulating factors is by the soft agar assay (31 ) . With this method and by using GM-CSF antibodies to check specificity, a similar time course of LPS-induced serum GM-CSF concentrations was found also in GalN/LPS-treated animals (data not shown). As shown in Table III , 20% of the total colony forming activity of serum measured 2 h after GalN/LPS administration to mice was due to GM-CSF.
Neutralization ofGM-CSF bioactivity in vivo Neutralization of GM-CSF in experimental endotoxic shock. To study the importance of endogenously produced GM-CSF for the pathogenesis of LPS-induced mortality, we administered a neutralizing monoclonal anti-mouse GM-CSF antibody (100 ,ug/mouse) shortly before lethal LPS injection. This treatment significantly reduced mortality in the antibody treated group (Fig. 4) . The mean TNF levels in the passively immunized group were 50% ofthe not pretreated group. However, due to great interindividual variability the differences between the groups were not significant (9.41±5.00 ng/ml vs. 18.98±9.59 ng/ml). In addition, the IL-6 levels in the serum samples of the animals, that had received the anti-GM-CSF antibody, were reduced to 26.94±7.15 ng/ml vs. 46.15±3.85 ng/ml in the control group (P < 0.05). It should be mentioned that according to the manufacturer's informations, the anti-GM-CSF antibody does not crossreact with murine IL-6.
Neutralization of GM-CSF in GalN-sensitized mice. Pretreatment of NMRI mice with a polyclonal rabbit anti-mouse GM-CSF antibody completely suppressed GM-CSF colony forming activity, significantly reduced serum TNF levels, and protected against liver injury (Table III) . Rabbit pre-immune serum was without any effect (data not shown).
Further experiments examined the question whether endogenous GM-CSF aggravated organ injury once TNFa is in the circulation. We therefore pretreated GalN-sensitized mice with the polyclonal GM-CSF antibody and challenged them by intravenous injection of 15 ,ug/kg TNFa instead of LPS. As shown in Table III , the antibody pretreatment failed to protect against septic liver failure induced by TNFa. Also, GM-CSF pretreatment had no significant influence on liver injury induced with a lower dose of 3 ,ug/kg TNFa in GalN-sensitized Role of GM-CSF in the development of early phase tolerance towards LPS LPS-induced early phase tolerance is known to be independent of antibody production and is induced by administration of subtoxic amounts of LPS as early as 1 h before a toxic challenge. We explored the possibility that tolerance is due to inhibition ofthe release ofthe enhancer GM-CSF. The data in Table  IV show that in tolerant mice, not developing septic liver failure upon challenge, the release of CSFs as well as of GM-CSF was enhanced rather than reduced, whereas TNF levels were partially suppressed. Thus, inhibition of CSFs is unlikely to account for a mechanism of tolerance.
Discussion
It has become increasingly evident that GM-CSF in addition to being an important hematopoietic growth factor is also a modulator ofgranulocyte and macrophage functions. In vitro experiments have shown that various leukocyte functions are subject to priming by GM-CSF. However, only little information exists about the contribution ofpriming by GM-CSF to processes in the whole organism such as inflammation. It was the aim of this study to investigate the role of GM-CSF in endotoxinbased models of inflammation and organ failure, i.e., LPS-induced shock and LPS-induced liver failure in GalN-sensitized mice, a quantifiable model for studying the basic pathophysiology ofseptic shock (21, 22) . In terms ofexperimental reproducibility in future experiments, it is noteworthy that the extent of GM-CSF potentiation ofTNF release and LPS toxicity showed a variability which was dependent on the actual LPS dose-response curve in the individual experiment.
The priming by GM-CSF of granulocytes and of cells derived from the monocyte lineage has been studied repeatedly. It is known that pretreatment of monocytes with GM-CSF primes these cells for endotoxin-induced TNF production (19) . Like LPS shock models, the GalN/LPS-induced hepatitis is an endotoxic model where the pivotal role of TNF for inducing hepatotoxicity is documented (24, 34, 35) . The present study demonstrates that GM-CSF is able to prime for LPSinduced TNF-production in vivo and that this priming may, in fact, have detrimental consequences for the whole organism. Beyond this statement, the protection against TNF-release and organ injury by anti-GM-CSF antibodies (see Table III and Results) suggests that GM-CSF participates endogenously in the response to LPS. The fact that no complete protection was achieved with the antibody is either a matter of dosage and titer, or it suggests that endogenous GM-CSF plays an auxiliary role as a modulator of the LPS-induced mediator production. Since LPS induced both, TNF and GM-CSF, the latter cytokine may act as an amplifier of LPS-induced TNF-production (Table III) .
Large discrepancies in the detectable amounts of different circulating cytokines after LPS challenge were found, i.e., TNF peak concentrations of 11 ng/ml compared with 125 pg/ml serum GM-CSF (Fig. 3) . This suggests that small amounts of GM-CSF may be able to enhance the LPS-induced TNF release, but we cannot rule out the existence ofhigh local concentrations of GM-CSF. The amounts of GM-CSF detected in GalN/ LPS treated mice 2 h after treatment were very low, i.e., the eight GM-CSF-specific colonies identified in the soft agar assay (Table III) correspond to the detection limit of 5 pg/ml of the GM-CSF ELISA used in the time course experiments (Fig. 3) . Other investigators have already reported that in humans no GM-CSF could be detected by ELISA after injection of small amounts of LPS (36) . Therefore, circulating GM-CSF may only inaccurately reflect local concentrations ofthis cytokine, a concept that has been recently described as the 'tip of the iceberg' (37) .
It is important to note that the initial TNF and GM-CSF release into serum occurred nearly simultaneously 30 min after LPS administration (Fig. 3) (33) . These kinetics and the fact that GM-CSF administration even 30 min after LPS challenge could enhance TNF production in vivo (Table I) suggest that endogenous GM-CSF may modulate TNF formation or release. This is corroborated further by our finding that administration of GM-CSF to GalN/TNFa-challenged mice failed to exacerbate hepatotoxicity and the anti-GM-CSF antibody did not protect against GalN/TNFa (Table III) .
IL-1 is another cytokine which has been implicated in the pathogenesis of septic shock (38) . Therefore, it was interesting to study whether GM-CSF would also enhance LPS-induced IL-1 production. However, because mouse serum was cytotoxic towards the cells used in the IL-1 bioassay, we were not able to determine IL-1 in vivo. To study the priming by GM-CSF on LPS-induced IL-1 production, we chose two different approaches: (a) we isolated spleen cells from mice challenged with LPS in vivo and measured the spontaneous IL-1 production of these cells after 20 h in culture; or (b) we prepared bone marrow cells and stimulated these cells in vitro with LPS. In either case LPS stimulated measurable IL-1 release that was further enhanced by pretreatment or preincubation with GM-CSF. Kinetic data obtained in vivo in mice showed that GM-CSF (this study, 39) and IL-1 production (40) both reached maximum levels 2 h after LPS injection. These results indicate that IL-1 release occurs with a time course also likely to be modulated by GM-CSF.
Besides the action on TNF and IL-1 production, GM-CSF also seems to affect circulating IL-6. This cytokine has also been associated with sepsis (41 ) as a reliable marker of mortality in experimental endotoxic shock in mice (42) and as a negative prognostic parameter for the severity of sepsis in humans (43) . Our observation that in mice pretreatment with anti-GM-CSF antibody caused resistance towards lethal LPS challenge, associated with reduced serum levels of IL-6, while GM-CSF pretreatment augmented IL-6 concentrations before subtoxic LPS challenge, confirm those conclusions drawn by others in different experimental settings. These in vivo data are also related to the report that GM-CSF, besides TNFa and LPS, induced considerable amounts of IL-6 from human polymorphonuclear leukocytes (10) . However, we cannot decide whether the attenuated IL-6 release in the anti-GM-CSF mAbtreated animals is caused directly by suppression of GM-CSF bioactivity or whether it is a consequence of reduced TNF production. These questions will be objects of further examination.
In the inflammatory response, both pro-as well as anti-inflammatory cytokines are known: TNF (23) , IL-l (44, 45) , and IFNy (46, 47) are able to aggravate LPS-induced shock or the fatal outcome of infectious diseases, whereas G-CSF (21 ), IL-4 (48), or IL-10 (49) are thought to represent factors terminating acute inflammatory processes. The interpretation ofthis study places GM-CSF in the role of a potentiator of the early stage of sepsis because it enhances the LPS-induced release of mediators such as TNF and IL-I at a time ofendogenous overstimulation of the nonspecific immune system. The reservation has to be acknowledged that this statement relates to the stage reflected in the animal model used here and does not exclude beneficial effects of so called proinflammatory cytokines if given at the appropriate time point. Nevertheless, our findings are of considerable practical interest for human therapy and may provide an explanation for some of the observed undesirable side reactions of clinically used GM-CSF, such as fever, chills, anorexia, weight loss, and pleural or pericardial inflammation (50) . For instance, patients with neutropenia after chemotherapy were reported to have elevated serum levels ofTNFa during GM-CSF therapy (5 1 ). In a study reported by Bar et al. 2 out of 14 cancer patients who received GM-CSF died of sepsis compared with 0 out of 12 patients treated with chemotherapy alone (52) . A summary on the unfavorable effects ofGM-CSF during treatment ofcancer patients is given in references 15 and 52. The doses applied clinically, i.e., up to 60 ug/kg GM-CSF daily ( 15, 53) , are comparable with the dose (50 gg/kg) used in our experiments. We conclude that the animal study reported here may help to explain some of the clinical observations and seems suitable to contribute a mechanistic interpretation of the aggravation of sepsis by GM-CSF treatment.
